M. Georgiadis

Phase II Neoadjuvant Trial of Paclitaxel by 96-Hour Continuous Infusion (CIVI) in Combination With Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non–Small-Cell Lung Cancer

S. Steinberg, Bruce E. Johnson, F. Kaye, 2002, American journal of clinical oncology.

Obesity and therapy-related toxicity in patients treated for small-cell lung cancer.

S. Steinberg, B. Johnson, D. Ihde, 1995, Journal of the National Cancer Institute.

Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.

W. Wilson, S. Steinberg, C. Takimoto, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations.

A. Gazdar, E. Russell, B. Johnson, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.

S. Steinberg, C. Takimoto, B. Johnson, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer.

J. Mulshine, M. Kelley, I. Avis, 1997, Chest.